Trial Profile
Phase II Non-Randomized Pre-Surgical Study Evaluating Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC) Who Are Eligible for Cytoreductive Nephrectomy.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 16 Jun 2023 Planned End Date changed from 30 Jun 2023 to 30 Jun 2025.
- 16 Jun 2023 Planned primary completion date changed from 30 Jun 2023 to 30 Jun 2025.
- 10 Oct 2022 Planned End Date changed from 30 Jun 2022 to 30 Jun 2023.